According to the latest "Top 10 Most Valuable R&D Projects" list released by Evaluate, a leading global biomedical data analysis firm, Idafang (PD-1/VEGF bispecific, Ivonescimab injection), a first-in-class PD-1/VEGF bispecific antibody developed by Zhongshan-based biopharmaceutical company Akeso, topped the global R&D pipeline by value, with a risk-adjusted net present value exceeding US$25.2 billion.

Ivonescimab is the only novel drug independently developed by a Chinese innovator among the top 10. Evaluate projects its global sales to reach US$8.5 billion in 2032, the highest worldwide, cementing its status as a next-gen cornerstone cancer therapy.

Founded in 2012, Akeso is a leading company specializing in the R&D, manufacturing and commercialization of first-in-class or best-in-class biologics.